Sodium Enoxaparine · Cardiovascular Sodium enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Adalimumab subcutaneous injection · Immunology Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
anti-TRBV9 monoclonal antibody infusions · Immunology / Oncology This monoclonal antibody targets and depletes T cells expressing the TRBV9 T-cell receptor beta variable segment, selectively eliminating a subset of pathogenic T cells in autoimmune and T-cell malignancy conditions.
BCD-055 · Oncology BCD-055 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-057 · Oncology BCD-057 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-063 · Immunology BCD-063 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases.
BCD-085 Q2W · Oncology BCD-085 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-085 Q4W · Oncology BCD-085 is a monoclonal antibody that blocks the PD-L1 checkpoint, enabling the immune system to recognize and attack cancer cells.
BCD-089 · Oncology BCD-089 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-100 · Oncology BCD-100 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-131 (pegdarbepoetin beta) · Hematology/Oncology BCD-131 is a pegylated erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor to stimulate red blood cell production.
BCD-132 · Oncology BCD-132 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-148 · Oncology BCD-148 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-178 · Oncology BCD-178 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-201 · Oncology BCD-201 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-217 · Oncology BCD-217 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-263 · Immunology / Rheumatology BCD-263 is a monoclonal antibody that binds to and inhibits IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases.
BCD-264 · Oncology BCD-264 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
BCD-281 · Oncology BCD-281 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
Cisplatin (or Carboplatin) · Oncology Cisplatin and carboplatin are platinum-based chemotherapy agents that bind to DNA and form cross-links, preventing DNA replication and transcription to kill rapidly dividing cancer cells.
Copaxone-Teva · Neurology; Immunology Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell activity in multiple sclerosis.